We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
German biopharmaceutical company Bayer has signed an exclusive license agreement with Cedilla Therapeutics, a US-based biotechnology company, for its precision oncology candidates. Under the terms of the agreement,
Pfizer has received the US Food and Drug Administration (FDA) approval for the Abrysvo vaccine to prevent disease caused by respiratory syncytial virus vaccine (RSV) in people aged
Australian pharmaceutical company Amplia Therapeutics has unveiled new preclinical data for its investigational drug AMP945, in combination with Folfirinox, in treating pancreatic cancer. AMP945 is an orally bioavailable
Lexicon Pharmaceuticals has received the US Food and Drug Administration (FDA) approval for Inpefa (sotagliflozin) to reduce the risk of cardiovascular death, and hospitalisation for heart failure. Inpefa
Pfizer has secured the US Food and Drug Administration (FDA) approval for Paxlovid (nirmatrelvir and ritonavir tablets), the company’s oral antiviral to treat adults with Covid-19. The drug
Krystal Biotech has received the US Food and Drug Administration (FDA) approval for Vyjuvek (beremagene geperpavec-svdt) to treat dystrophic epidermolysis bullosa (DEB) in patients aged six months and
US-based pharmaceutical company AbbVie has received the US Food and Drug Administration (FDA) approval for Rinvoq (upadacitinib) to treat a type of active Crohn’s disease in adults. Rinvoq
Swiss pharmaceutical firm Roche has unveiled positive results for its new drug, fenebrutinib, in treating adults with relapsing multiple sclerosis (RMS), from the Phase 2 FENopta study. Fenebrutinib
Astellas Pharma and Sony Corporation have signed an agreement for a research collaboration to discover a novel Antibody-Drug Conjugate (ADC) platform in oncology. Under the collaboration, Astellas and
Gilead Sciences and Arcus Biosciences have expanded their existing research collaboration, focusing on oncology treatment to include therapies for inflammatory diseases. Under the terms of the expanded collaboration,